Advances in treatment of age-related macular degeneration

International Journal of Ophthalmology

Volumn 8, Issue 5, 2008, Pages 985-989

  Yan, Yan ^a   Wang, Ling ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Therapy

Indexed keywords

AL 39324; ANECORTAVE; BEVACIZUMAB; BEVASIRANIB SODIUM; EVIZON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEGAPTANIB; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RATAANE; SMALL INTERFERING RNA; SQUALAMINE; SQUALAMINE LACTATE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN TRAP; VATALANIB; VERTEPORFIN;

ARTICLE; CLINICAL PROTOCOL; DIET SUPPLEMENTATION; HUMAN; LASER COAGULATION; MAINTENANCE THERAPY; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TRANSPLANTATION;

EID: 45149109428     PISSN: 16725123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Tomany SC, Wang JJ, van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004;111:1280-1287
2. Age-Related Eye Disease Study Research Group. A randomized, place-bo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436
3. van Leeuwen R, Vingerling JR, Hofman A, et al. Cholesterol lowering drugs and risk of age-related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255-256
4. McGwin G Jr, Xie A, Owsley C. The use of cholesterol-lowering medications and agerelated macular degeneration. Ophthalmology 2005; 112: 488-494
5. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. Ophthalmology 1998;105(1):11-23
6. Olk RJ, Friberg TR, Stickney KL, et al. Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two year results of a randomized pilot study. Ophthalmology 1999;106(11):2082-2090
7. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994;112:500-509
8. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-1114
9. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report Nol. Arch Ophthalmol 1999;117:1329-1345
10. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207
11. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-560
12. Marcus DM, Peskin E, Maguire M, et al. AMDRT Research Group. The agerelated macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol 2004;138:818-828
13. Auer C, Tao Tran V, Herbort CP. Transpupillary thermotherapy for occult subfoveal neovessels in age-related macular degeneration: importance of patient pigmentation for the determination of laser settings. Klin Monatsbl Augenheilkd 2002;219:250-253
14. Reichel E, Park CH, Duker JS, et al. Transpupillary thermotherapy for occult neovascularization. Invest Ophthalmol Vis Sci 2004;45:E-Abstract 3132
15. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-2816
16. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444
17. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431
18. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112(6):1035-1047
19. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110:2372-2383
20. Schmidt-Erfurth U, Michels S. Michels R, et al. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 2005;15:482-485
21. Slakter JS, Rochow TW, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006;113:3-13
22. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 121:667-673
23. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522,e1-e14
24. Takahashi K, Saishin Y, Silva RL, et al. Systemic of intraocular administration of VEGF receptor kinase inhibitors causes regression of choroidal neovascularization. Invest Cphthalmol Vis Sci 2005;46: E-Abstract 1423
25. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13:225-234
26. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004;24:132-138
27. Garcia CA, Quiroz-Mereado H, Uwaydat S, et al. A phase I/II trial of intravenous squalamine lactate for treatment of choroidal neovascularization in age related macular degeneration (ARMD). Invest Ophthalmol Vis Sci 2004;45:2362
28. Nambu H, Nambu R, Melia M, et al. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3650-3655
29. Renno RZ, Terada Y, Haddadin MJ, et al. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 2004;122:1002-1011
30. Mori K, Gelbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002;43:2428-2434
31. Balaggan KS, Binley K, Esapa M, et al. EIAV vector delivery of angiostatin or endostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. Gene Ther 2006;13(15):1153-1365
32. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304
33. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22
34. Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-993
35. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006; 124:1532-1542
36. Hawkins BS, Bressler NM, Miskala PH, et al. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings: SST report no. 11. Ophthalmology 2004;111:1967-1980
37. Bressler NM, Bressler SB, Childs AL, et al. Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findings: SST report no. 13. Ophthalmology 2004;111:1993-2006
38. Zhang X, Ren BC. Recent advance of the study on treatment for age-related macular degeneration. Int J Ophthalmol (Guoji Yanke Zazhi) 2007;7(6):1674-1676
39. Falkner Cl, Leitich H, Frommlet F, et al. The end of submacular surgery for age-related macular degeneration? A meta-analysis. Graefe's Arch Clin Exp Ophthalmol 2007;245(4):490-501
40. Tang Y, Tang LS. Progress in the study of treatment of age-related macular degeneration. Int J Ophthalmol (Guoji Yanke Zazhi) 2006;6(6):1393-1396